You can't simply base things on the Mipomersen deal just because it has come from ISIS portfolio - things vary so greatly from deal to deal that they are rarely repeated in exactly the same fashion or for exactly the same financial consideration for what it's worth the deal was one of the largest at the time biotech moving on biotech & Genzyme was really out to make it very visual that they meant business industry wide.
Sure an ANP deal will probably come forward in time provided it continues to meet desired objectives but i think you're only misleading yourselves if your viewing a Mipomersen size deal as a guaranteed outcome. More likely case imo would be something similar to Excaliard - it is more inline with big pharmas strategy at this point - alot of buckling the purse strings since 2007 with Mipomersen & they prefer to get the claws in without having to guarantee a large sum for a drug that potentially fails. Milestones heavily weight out that risk.
ANP Price at posting:
20.0¢ Sentiment: None Disclosure: Held
